Back to Awarded Treatment Trials
Awarded Trial: 01T-436
Grant ID
01T-436
Illness
Schizophrenia
Primary Drug/Intervention
Folic Acid
Primary Dosage
2 mg
Secondary Drug Intervention
B12
Secondary Dosage
400 mg
Other Drug/Intervention
Pyridoxine
Other Dosage
25 mg
Status
Completed
Investigator
Belmaker
Sample Size
42
Duration of Study Period for Each Subject
6 months
Outcome Measurements
PANSS, AIMS
Results
Forty two schizophrenic patients with plasma homocysteine above 15 micromoles per liter were treated with folic acid + B12 + pyridoxine for three months and with placebo for three months in a randomized, blinded, crossover design. Homocysteine levels declined on vitamin therapy compared to placebo. There was a signifcant reduction in total PANSS score and an improvement on the Wisonsin Card Sort test during the vitamin treatment.
Publication
Levine J, Stahl Z, Sela BA, Ruderman V, Shumaico O, Babushkin I, Osher Y, Bersudsky Y, Belmaker RH. Homocysteine-Reducing Strategies Improve Symptoms in Chronic Schizophrenic Patients with Hyperhomocysteinemia. Biological Psychiatry 2006 Aug 1;60(3):265-9.
Link
http://www.ncbi.nlm.nih.gov/pubmed/16412989
PI Name
Robert Belmaker
Degree
MD
Center
Beersheva Mental Health Center
Institution
Ben Gurion University
Address
P.O. Box 4600
City or Town
Beersheva
State or Province
N/A
Zip or Postal Code
N/A
Country
Israel
Email Address
belmaker@bgu.ac.il